Published in Cancer Cell on April 01, 2004
Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer (2009) 6.28
Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol (2010) 6.04
Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov (2012) 4.72
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med (2011) 4.51
Antibody validation. Biotechniques (2010) 4.42
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene (2008) 4.13
Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol (2011) 4.12
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol (2010) 3.32
The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer (2012) 2.79
HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res (2006) 2.74
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell (2004) 2.60
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell (2014) 2.44
Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol (2005) 2.35
Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell (2008) 2.21
The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci (2008) 2.00
Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys (2008) 1.97
Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol (2008) 1.95
The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther (2008) 1.90
The role of HER2 in cancer therapy and targeted drug delivery. J Control Release (2010) 1.88
The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. Proc Natl Acad Sci U S A (2005) 1.84
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther (2011) 1.84
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol (2013) 1.81
Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog (2012) 1.75
Ligand-induced ErbB receptor dimerization. Exp Cell Res (2008) 1.73
Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Nat Rev Clin Oncol (2010) 1.69
Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res (2008) 1.50
Distribution of resting and ligand-bound ErbB1 and ErbB2 receptor tyrosine kinases in living cells using number and brightness analysis. Proc Natl Acad Sci U S A (2010) 1.45
The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med (2007) 1.37
A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin Cancer Res (2008) 1.35
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist (2013) 1.35
Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest (2008) 1.34
Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosis. J Cell Mol Med (2008) 1.27
Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol (2012) 1.26
Structural basis for high-affinity HER2 receptor binding by an engineered protein. Proc Natl Acad Sci U S A (2010) 1.24
Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer. Breast Cancer Res (2009) 1.20
Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism. Breast Cancer Res (2011) 1.18
Building better monoclonal antibody-based therapeutics. Nat Rev Cancer (2015) 1.15
Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment. Front Oncol (2013) 1.14
Interaction of antibodies with ErbB receptor extracellular regions. Exp Cell Res (2008) 1.13
Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer (2012) 1.12
Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling. Proc Natl Acad Sci U S A (2012) 1.12
Muc4-ErbB2 complex formation and signaling in polarized CACO-2 epithelial cells indicate that Muc4 acts as an unorthodox ligand for ErbB2. Mol Biol Cell (2006) 1.11
Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J Clin Oncol (2010) 1.10
Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. J Transl Med (2012) 1.10
HER2 breast cancer therapies: a review. Biologics (2009) 1.09
Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies. J Biol Chem (2011) 1.08
Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer. PLoS Comput Biol (2012) 1.06
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action. Breast Cancer Res (2011) 1.06
Genetic and biochemical alterations in non-small cell lung cancer. Biochem Res Int (2012) 1.05
A structural perspective on the regulation of the epidermal growth factor receptor. Annu Rev Biochem (2015) 1.04
High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. PLoS One (2011) 1.03
A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes. Immunology (2014) 1.03
Quantitative characterization of the large-scale association of ErbB1 and ErbB2 by flow cytometric homo-FRET measurements. Biophys J (2008) 1.02
erbB3 is an active tyrosine kinase capable of homo- and heterointeractions. Mol Cell Biol (2013) 1.02
Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J Clin Oncol (2009) 1.02
HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks. Breast Cancer Res (2007) 1.02
Present and future evolution of advanced breast cancer therapy. Breast Cancer Res (2010) 1.01
Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses. Oncoimmunology (2013) 1.01
HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells. BMC Cell Biol (2009) 1.00
Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo. J Biol Chem (2011) 0.99
Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes. Oncogene (2008) 0.99
2nd PEGS Annual Symposium on Antibodies for Cancer Therapy: April 30-May 1, 2012, Boston, USA. MAbs (2012) 0.99
Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs. Oncogenesis (2012) 0.99
Roles for neuregulins in human cancer. Clin Exp Metastasis (2004) 0.98
Enhancement of cell type specificity by quantitative modulation of a chimeric ligand. J Biol Chem (2008) 0.97
Chemopreventive activity of vitamin E in breast cancer: a focus on γ- and δ-tocopherol. Nutrients (2011) 0.96
The Mysterious Ways of ErbB2/HER2 Trafficking. Membranes (Basel) (2014) 0.96
Major clinical research advances in gynecologic cancer in 2012. J Gynecol Oncol (2013) 0.96
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochim Biophys Acta (2014) 0.96
A growing family: adding mutated Erbb4 as a novel cancer target. Cell Cycle (2010) 0.95
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. Oncologist (2014) 0.95
Emerging antibody combinations in oncology. MAbs (2011) 0.94
ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1. J Biol Chem (2014) 0.93
Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study. Breast Cancer Res (2014) 0.93
Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic. J Biomol Struct Dyn (2012) 0.93
Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer. Br J Cancer (2014) 0.92
Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer. ISRN Oncol (2012) 0.92
ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. J Clin Invest (2013) 0.92
Design, synthesis, and docking studies of peptidomimetics based on HER2-herceptin binding site with potential antiproliferative activity against breast cancer cell lines. Chem Biol Drug Des (2009) 0.92
Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action. World J Biol Chem (2010) 0.91
Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer. J Proteome Res (2013) 0.91
Targeted therapy in HER2-positive breast cancer. Biomed Rep (2013) 0.91
Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors. Jpn J Clin Oncol (2009) 0.91
A new therapeutic antibody masks ErbB2 to its partners. Cancer Cell (2004) 0.91
Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice. Oncotarget (2014) 0.91
Two dimensions in targeting HER2. J Clin Oncol (2014) 0.90
Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. Br J Cancer (2012) 0.90
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. Br J Cancer (2014) 0.90
EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem (2012) 0.90
HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer. Breast Care (Basel) (2013) 0.90
Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer. Oncologist (2014) 0.89
Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice. J Adv Pract Oncol (2015) 0.89
Transmembrane helix-helix interactions involved in ErbB receptor signaling. Cell Adh Migr (2010) 0.89
Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects. World J Gastroenterol (2014) 0.89
Anatomy of β-strands at protein-protein interfaces. ACS Chem Biol (2014) 0.89
A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas. Neoplasia (2008) 0.88
Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncol (2012) 0.88
Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes. J Biol Chem (2011) 0.88
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature (2003) 6.78
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell (2009) 6.02
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem (2002) 5.63
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol (2008) 5.54
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res (2008) 5.34
Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc Natl Acad Sci U S A (2008) 5.14
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell (2003) 5.06
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell (2002) 4.34
EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell (2003) 4.23
Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol (2011) 4.12
A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res (2008) 3.93
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res (2006) 3.34
Structure of the extracellular region of HER3 reveals an interdomain tether. Science (2002) 3.19
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol (2010) 3.06
Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure (2008) 2.79
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell (2004) 2.60
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat (2010) 2.55
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol (2012) 2.43
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell (2011) 2.14
Glucose and weight control in mice with a designed ghrelin O-acyltransferase inhibitor. Science (2010) 2.12
Oncogenic ERBB3 mutations in human cancers. Cancer Cell (2013) 2.06
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol (2005) 1.99
Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res (2010) 1.98
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother (2005) 1.98
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res (2013) 1.89
Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165. J Biol Chem (2002) 1.89
The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. Proc Natl Acad Sci U S A (2005) 1.84
Structural insights into the catalytic mechanism of cyclophilin A. Nat Struct Biol (2003) 1.78
Structure and Notch receptor binding of the tandem WWE domain of Deltex. Structure (2005) 1.76
Dystroglycan organizes axon guidance cue localization and axonal pathfinding. Neuron (2012) 1.76
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res (2009) 1.70
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol (2009) 1.66
Structural basis for ligand and heparin binding to neuropilin B domains. Proc Natl Acad Sci U S A (2007) 1.66
Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res (2011) 1.66
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res (2010) 1.63
Interactions between Hedgehog proteins and their binding partners come into view. Genes Dev (2010) 1.54
Structure and stability of the ankyrin domain of the Drosophila Notch receptor. Protein Sci (2003) 1.54
PPM1H is a p27 phosphatase implicated in trastuzumab resistance. Cancer Discov (2011) 1.50
Mutational analysis of Norrin-Frizzled4 recognition. J Biol Chem (2006) 1.48
Structure of a heparin-dependent complex of Hedgehog and Ihog. Proc Natl Acad Sci U S A (2006) 1.47
The mode of Hedgehog binding to Ihog homologues is not conserved across different phyla. Nature (2008) 1.47
Crystal structure of the CaV2 IQ domain in complex with Ca2+/calmodulin: high-resolution mechanistic implications for channel regulation by Ca2+. Structure (2008) 1.44
Suppressor of fused regulates Gli activity through a dual binding mechanism. Mol Cell Biol (2004) 1.38
Netrin binds discrete subdomains of DCC and UNC5 and mediates interactions between DCC and heparin. J Biol Chem (2003) 1.37
The crystal structures of EAP domains from Staphylococcus aureus reveal an unexpected homology to bacterial superantigens. J Biol Chem (2005) 1.37
Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. J Mol Biol (2002) 1.33
Preclinical studies with Erlotinib (Tarceva). Semin Oncol (2003) 1.29
Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res (2004) 1.29
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res (2012) 1.27
A single ligand is sufficient to activate EGFR dimers. Proc Natl Acad Sci U S A (2012) 1.24
Transient mammalian cell transfection with polyethylenimine (PEI). Methods Enzymol (2013) 1.24
Dally-like core protein and its mammalian homologues mediate stimulatory and inhibitory effects on Hedgehog signal response. Proc Natl Acad Sci U S A (2010) 1.21
Mechanistic insights into the activation of oncogenic forms of EGF receptor. Nat Struct Mol Biol (2011) 1.21
All mammalian Hedgehog proteins interact with cell adhesion molecule, down-regulated by oncogenes (CDO) and brother of CDO (BOC) in a conserved manner. J Biol Chem (2010) 1.17
In vitro enzymatic characterization of near full length EGFR in activated and inhibited states. Biochemistry (2009) 1.16
Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res (2012) 1.16
Structural basis for heteromeric assembly and perinuclear organization of keratin filaments. Nat Struct Mol Biol (2012) 1.10
A forward genetic screen in mice identifies Sema3A(K108N), which binds to neuropilin-1 but cannot signal. J Neurosci (2010) 1.10
Kinetic and structural studies on interactions between heparin or heparan sulfate and proteins of the hedgehog signaling pathway. Biochemistry (2007) 1.10
The crystal structures of EDA-A1 and EDA-A2: splice variants with distinct receptor specificity. Structure (2003) 1.10
Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association. J Biol Chem (2002) 1.07
KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension (2002) 1.06
Perspectives on anti-HER monoclonal antibodies. Oncology (2002) 1.06
The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1. J Biol Chem (2003) 1.04
Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. Clin Breast Cancer (2011) 1.01
Structure of the protein core of the glypican Dally-like and localization of a region important for hedgehog signaling. Proc Natl Acad Sci U S A (2011) 1.00
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J Pharmacokinet Pharmacodyn (2010) 0.97
Regulation of the small GTPase Rap1 and extracellular signal-regulated kinases by the costimulatory molecule CTLA-4. Mol Cell Biol (2005) 0.95
Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering. J Med Chem (2014) 0.95
Proteolytic processing of ErbB4 in breast cancer. PLoS One (2012) 0.90
Structure-based mutagenesis of the substrate-recognition domain of Nrdp1/FLRF identifies the binding site for the receptor tyrosine kinase ErbB3. Protein Sci (2007) 0.88
Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. Cancer Chemother Pharmacol (2011) 0.87
The ErbB4 extracellular region retains a tethered-like conformation in the absence of the tether. Protein Sci (2011) 0.87
Crystal structure of Caenorhabditis elegans HER-1 and characterization of the interaction between HER-1 and TRA-2A. Proc Natl Acad Sci U S A (2004) 0.84
Memo is homologous to nonheme iron dioxygenases and binds an ErbB2-derived phosphopeptide in its vestigial active site. J Biol Chem (2007) 0.83
Tyrosine phosphorylation of mig6 reduces its inhibition of the epidermal growth factor receptor. ACS Chem Biol (2013) 0.83
Decreasing the rate of metabolic ketone reduction in the discovery of a clinical acetyl-CoA carboxylase inhibitor for the treatment of diabetes. J Med Chem (2014) 0.82
Ready to partner. Nat Struct Biol (2003) 0.82
Discovery of novel non-synonymous SNP variants in 988 candidate genes from 6 centenarians by target capture and next-generation sequencing. Mech Ageing Dev (2013) 0.82
Toward an effective targeted chemotherapy for multiple myeloma. Clin Cancer Res (2009) 0.82
An Fc domain protein-small molecule conjugate as an enhanced immunomodulator. J Am Chem Soc (2014) 0.80
Structure-guided inhibitor design for human acetyl-coenzyme A carboxylase by interspecies active site conversion. J Biol Chem (2011) 0.80
Discovery and optimization of a novel spiropyrrolidine inhibitor of β-secretase (BACE1) through fragment-based drug design. J Med Chem (2012) 0.79
Molecular dynamics simulations of transitions for ECD epidermal growth factor receptors show key differences between human and drosophila forms of the receptors. Proteins (2013) 0.78
Deconstruction of activity-dependent covalent modification of heme in human neutrophil myeloperoxidase by multistage mass spectrometry (MS(4)). Biochemistry (2012) 0.78
Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors. Bioorg Med Chem Lett (2013) 0.77
Generating mammalian stable cell lines by electroporation. Methods Enzymol (2013) 0.75
A monkey wrench in the kinase machine. Nat Struct Mol Biol (2007) 0.75